DRUG DISCOVERY CORE FACILITY (DDCF)

这个子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， NCRR赠款不直接向子项目或子项目工作人员提供资金。 摘要： 在该机构建立药物发现核心设施（DDCF）的总体目标是通过集中和协调的研究合作，加强佛罗里达A&M大学药物发现的研究基础设施。这是一个承诺，以建立和扩大在校园里发起的研究活动，利用生物医学研究的成功，在过去的20年中遇到的调查人员。尽管化学治疗剂及其作用机制有了重大发现，但对具有新作用机制的新化学实体用于治疗某些癌症、神经退行性疾病和新出现的感染性疾病的需求仍然很高。 因此，计划通过研究合作积极开发新的治疗剂。 过去最活跃和富有成效的研究合作之一是药物设计和合成领域，以及各种生物活性实体的药理学和生物化学研究。这些不同的项目得到了美国国立卫生研究院（MBRS，MARC，BRIDGE和RCMI计划），国防部和美国宇航局研究补助金的支持。 这些项目中的每一个都是在药学院和艺术与科学学院，特别是化学系的研究人员之间进行研究合作的。DDCF的成立将扩大和加强校园现有合作的成就。该机构药物开发战略的重点将是开发可用于治疗神经退行性疾病（帕金森病、中风）、癌症（乳腺癌和前列腺癌）和新发传染病的新型候选药物。这项活动的另一个动力是采取步骤，纠正参与药物发现研究的少数民族研究人员人数持续不均衡的问题。 在历史上的黑人学院和大学植入药物发现研究的困难是由于缺乏足够的资源，训练有素的调查人员和药物发现的研究基础设施。发展筹资框架的建立将大大有助于满足这一迫切需要。 这项研究得到了NIH/NCRR/RCMI G12 RR 03020的支持。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT: The overall goal of establishing a Drug Discovery Core Facility (DDCF) at the institution is to strengthen the research infrastructure for drug discovery at Florida A&M University through research collaboration in a focused and coordinated effort. It is a commitment to build and expand the investigator-initiated research activities on campus, taking advantage of the biomedical research successes encountered by the investigators during the past 20 years. Despite significant discovery of chemotherapeutic agents and their mechanisms of action, the need for new chemical entities having new mechanisms of action for the treatment of certain cancer, neurodegenerative diseases and the emerging infectious diseases remains high. Therefore, an aggressive exploitation of new curative agents is planned through research collaboration. One of the most active and productive research collaborations in the past has been in the areas of drug design and synthesis, as well as the pharmacological and biochemical investigations of various biologically active entities. These diverse projects have been supported by NIH, (MBRS, MARC, BRIDGE and RCMI Programs), Department of Defense and research grant awards by NASA. Each of these projects has been pursued with research collaboration among the investigators in the College of Pharmacy and the College of Arts and Sciences, especially the Department of Chemistry. The establishment of the DDCF will expand and strengthen the achievements of the existing collaboration on campus. The focus of the institution's drug development strategy will be to develop novel drug candidates that can be used for the treatment of neurodegenerative diseases (Parkinson's disease, stroke), cancer (breast and prostate cancers) and emerging infectious diseases. Another impetus for this activity is to take a step towards a remedy for the persistent disparity in the number of minority investigators involved in drug discovery research. The difficulty in implanting drug discovery research at historically black colleges and universities is due to the lack of adequate resources, trained investigators and research infrastructure for drug discovery. The establishment of the DDCF will go a long way into facilitating this dire need. This research is supported by NIH/NCRR/RCMI G12RR03020.